Conference Track

Resistance and Management of Treatment-Experienced Patients

Source: CCO Official Conference Coverage of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention

Capsule Summaries

Very Low Prevalence of Combinations of NNRTI Mutations Associated With Reduced Susceptibility to Etravirine in Clinical Samples
Case Reports Suggest Cross-Resistance May Limit Ability to Administer Integrase Inhibitors Sequentially
BLQ Study: Week 24 Interim Analysis Demonstrates Efficacy of Darunavir/Ritonavir Plus Enfuvirtide and OBR in Multiclass-Experienced Cohort
Relationship Between Baseline Mutations and Outcomes in TITAN Study Comparing Darunavir/Ritonavir and Lopinavir/Ritonavir in Lopinavir-Naive, Treatment-Experienced Patients
Darunavir/Ritonavir Superior to Lopinavir/Ritonavir in Lopinavir-Naive, Treatment-Experienced Patients After 48 Weeks of Therapy
Pretreatment Resistance Mutations Reduce Antiretroviral Therapy Response Rates
Pooled Data From MOTIVATE 1 and 2 Confirm Increased Efficacy of Maraviroc When Combined With at Least 1 Active Agent in OBR
Pooled Analysis of MOTIVATE 1 and 2 Confirms Efficacy, Supports Proposed Twice-Daily Administration
DUET-1 and -2: Etravirine (TMC125) Plus Darunavir/Ritonavir-Based Regimen Associated With High Rates of Viral Suppression in Treatment-Experienced HIV-Infected Patients

Expert Analysis

Resistance and Management of Treatment-Experienced Patients

Faculty:
W. David Hardy, MD Charles B. Hicks, MD William G. Powderly, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss new insights into the impact of baseline resistance on response to antiretroviral therapy, both in treatment-naive and treatment-experienced patients
Summarize the findings of recent studies of new antiretroviral agents in existing and novel classes in the management of treatment-experienced patients
Describe recent observations regarding the selection of resistance mutations in patients with virologic failure in clinical studies of antiretroviral agents

CME CREDIT INFORMATION

Release Date: 09/28/07

Expiration Date: 09/27/08

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.3 contact hours (0.13 CEUs)

Registered Nurses: 1.3 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.